Standard
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA) : a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. / Kobbernagel, Helene E.; Buchvald, Frederik F.; Haarman, Eric G.; Casaulta, Carmen; Collins, Samuel A.; Hogg, Claire; Kuehni, Claudia E.; Lucas, Jane S.; Moser, Claus E.; Quittner, Alexandra L.; Raidt, Johanna; Rosthoj, Susanne; Sorensen, Anne L.; Thomsen, Kim; Werner, Claudius; Omran, Heymut; Nielsen, Kim G.
In:
The Lancet Respiratory Medicine, Vol. 8, No. 5, 2020, p. 493-505.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Kobbernagel, HE, Buchvald, FF, Haarman, EG, Casaulta, C, Collins, SA, Hogg, C, Kuehni, CE, Lucas, JS
, Moser, CE, Quittner, AL, Raidt, J
, Rosthoj, S, Sorensen, AL, Thomsen, K, Werner, C, Omran, H
& Nielsen, KG 2020, '
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial',
The Lancet Respiratory Medicine, vol. 8, no. 5, pp. 493-505.
https://doi.org/10.1016/S2213-2600(20)30058-8APA
Kobbernagel, H. E., Buchvald, F. F., Haarman, E. G., Casaulta, C., Collins, S. A., Hogg, C., Kuehni, C. E., Lucas, J. S.
, Moser, C. E., Quittner, A. L., Raidt, J.
, Rosthoj, S., Sorensen, A. L., Thomsen, K., Werner, C., Omran, H.
, & Nielsen, K. G. (2020).
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
The Lancet Respiratory Medicine,
8(5), 493-505.
https://doi.org/10.1016/S2213-2600(20)30058-8Vancouver
Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA, Hogg C et al.
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
The Lancet Respiratory Medicine. 2020;8(5):493-505.
https://doi.org/10.1016/S2213-2600(20)30058-8Author
Kobbernagel, Helene E. ; Buchvald, Frederik F. ; Haarman, Eric G. ; Casaulta, Carmen ; Collins, Samuel A. ; Hogg, Claire ; Kuehni, Claudia E. ; Lucas, Jane S. ; Moser, Claus E. ; Quittner, Alexandra L. ; Raidt, Johanna ; Rosthoj, Susanne ; Sorensen, Anne L. ; Thomsen, Kim ; Werner, Claudius ; Omran, Heymut ; Nielsen, Kim G. / Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA) : a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. In: The Lancet Respiratory Medicine. 2020 ; Vol. 8, No. 5. pp. 493-505.
Bibtex
@article{b21a32eb06334bcbbc2ecdb6542a8f84,
title = "Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial",
author = "Kobbernagel, {Helene E.} and Buchvald, {Frederik F.} and Haarman, {Eric G.} and Carmen Casaulta and Collins, {Samuel A.} and Claire Hogg and Kuehni, {Claudia E.} and Lucas, {Jane S.} and Moser, {Claus E.} and Quittner, {Alexandra L.} and Johanna Raidt and Susanne Rosthoj and Sorensen, {Anne L.} and Kim Thomsen and Claudius Werner and Heymut Omran and Nielsen, {Kim G.}",
year = "2020",
doi = "10.1016/S2213-2600(20)30058-8",
language = "English",
volume = "8",
pages = "493--505",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "The Lancet Publishing Group",
number = "5",
}
RIS
TY - JOUR
T1 - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA)
T2 - a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
AU - Kobbernagel, Helene E.
AU - Buchvald, Frederik F.
AU - Haarman, Eric G.
AU - Casaulta, Carmen
AU - Collins, Samuel A.
AU - Hogg, Claire
AU - Kuehni, Claudia E.
AU - Lucas, Jane S.
AU - Moser, Claus E.
AU - Quittner, Alexandra L.
AU - Raidt, Johanna
AU - Rosthoj, Susanne
AU - Sorensen, Anne L.
AU - Thomsen, Kim
AU - Werner, Claudius
AU - Omran, Heymut
AU - Nielsen, Kim G.
PY - 2020
Y1 - 2020
U2 - 10.1016/S2213-2600(20)30058-8
DO - 10.1016/S2213-2600(20)30058-8
M3 - Journal article
VL - 8
SP - 493
EP - 505
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
SN - 2213-2600
IS - 5
ER -
